Journal
STEROIDS
Volume 153, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.steroids.2019.108520
Keywords
Glucocorticoid receptor; Chaperones; Pkbp51; SUMO
Funding
- Max Planck Society, Germany
- University of Buenos Aires
- CONICET
- Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina
- FOCEM-Mercosur [COF 03/11]
Ask authors/readers for more resources
In order to adequately respond to stressful stimuli, glucocorticoids (GCs) target almost every tissue of the body. By exerting a negative feedback loop in the hypothalamic-pituitary-adrenal (HPA) axis GCs inhibit their own synthesis and restore homeostasis. GCs actions are mostly mediated by the GC receptor (GR), a member of the nuclear receptor superfamily. Alterations of the GR activity have been associated to different diseases including mood disorders and can lead to severe complication. Therefore, understanding the molecular complexity of GR modulation is mandatory for the development of new and effective drugs for treating GR-associated disorders. FKBP51 is a GR chaperone that has gained much attention because it is a strong inhibitor of GR activity and has a crucial role in psychiatric diseases. Both GR and FKBP51 activity are regulated by SUMOylation, a post-translational (PTM). In this review, we focus on the impact of SUMO-conjugation as a regulator of this pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available